Cargando…

The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer

Detalles Bibliográficos
Autores principales:	Reale, Maria Lucia, De Luca, Emmanuele, Di Maio, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225132/ https://www.ncbi.nlm.nih.gov/pubmed/32420084 http://dx.doi.org/10.21037/tlcr.2020.02.02

Ejemplares similares

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

Taking it up a notch: a promising immunotherapy against small cell lung cancer
por: Apaydin, Alanisse A., et al.
Publicado: (2023)

Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
por: Deboever, Nathaniel, et al.
Publicado: (2022)

Botulinum Toxin Injection in Truncal Dystonia: Time to Take Note
por: Choudhury, Supriyo, et al.
Publicado: (2020)

Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2019)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer
por: Sattler, Martin, et al.
Publicado: (2023)

“From chemo to chemo”—the temporal paradox of chemotherapy
por: Moskalewicz, Marcin, et al.
Publicado: (2021)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

The Changing Face of Lung Cancer: Oligometastatic Renal Metastasis Post Chemo-Immunotherapy Combination
por: Matini, Elvis, et al.
Publicado: (2023)

Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases
por: Rutkowski, Piotr, et al.
Publicado: (2023)

Commentary: What is the key issue in high take-off of the left coronary artery?
por: Kobayashi, Junjiro
Publicado: (2021)

DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy
por: De Smet, Charles
Publicado: (2023)

IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?
por: Vagia, Elena, et al.
Publicado: (2020)

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer
por: Käsmann, Lukas, et al.
Publicado: (2019)

The Key-Note to Success
Publicado: (1895)

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
por: Fonsatti, Ester, et al.
Publicado: (2004)

Top-of-the-art cytometry as a novel tool to aid in lung cancer immunotherapy
por: Mondelo-Macía, Patricia, et al.
Publicado: (2023)

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
por: Celsa, Ciro, et al.
Publicado: (2023)

Radiotherapy: the key to immunotherapy ignition?
por: Luterstein, Elaine, et al.
Publicado: (2017)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
por: Yeku, Oladapo, et al.
Publicado: (2020)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy
por: Helweg, Laureen P., et al.
Publicado: (2022)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
por: Cali Daylan, Ayse Ece, et al.
Publicado: (2023)

It takes all sorts to make a world: geographical differences and the future perspective of molecular testing in non-small cell lung cancer
por: Bertoglio, Pietro, et al.
Publicado: (2020)

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve
por: Zhou, Qing, et al.
Publicado: (2023)

Single-cell insights into the dynamic tumor microenvironment changes during immunotherapy of non-small cell lung cancer
por: Prazanowska, Karolina Hanna, et al.
Publicado: (2023)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer
por: Chen, Hai, et al.
Publicado: (2021)

Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?
por: Ng, Matthew C. H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lm9en01sq1uu4q8c6olvodp42u